 The endpoints of the study will be examined at baseline and after each treatment period corresponding to 8, 16, and 24 weeks after randomization. The following parameters are determined after each treatment period: Albuminuria determined from three consecutive 24 hours urine collections, kidney function GFR by plasma clearance of 51Cr-EDTA , and 24 hour ambulatory blood pressure TM-24202421. Furthermore, the concentrations of TGF-ß, sodium, creatinine, and carbamide in the 24 hour urinary samples are determined. The plasma concentration of albumin, renin, angiotensin II, and aldosterone is measured. 